2nd International Conference on Fostering Interdisciplinary Research In Health Sciences (ICFIRHS) 2019 (01-May-2019)        |

Journal :   Research Journal of Pharmacy and Technology

Volume No. :   12

Issue No. :  6

Year :  2019

Pages :   3098-3104

ISSN Print :  0974-3618

ISSN Online :  0974-360X


Registration

Allready Registrered
Click to Login

Translational Chemotherapy for triple negative Breast Cancer - A Review on significance of poly (ADP-ribose) polymerase 1 (PARP 1) inhibitors



Address:   Elizabeth Eldhose1, B. Gowramma1*, Manal Mohammed2, R. Kalirajan1, L. Kaviarasan1
1Department of Pharmaceutical Chemistry, JSS College of Pharmacy, Udhagamandalam, Tamilnadu,
2Department of Pharmaceutical Chemistry, KTN College of Pharmacy, Kerala.
*Corresponding Author
DOI No: 10.5958/0974-360X.2019.00524.9

ABSTRACT:
Breast Cancer, the most common cancer observed in women around the world[1], accounts for 12% of all new cancer cases and nearly 25% of all cancers in women[2]. Breast Cancer, a heterogenous disease, is evident over a broad differentiation in phenotypes and morphological profiles, with an after effect of various clinical behaviours[3]. From an estimated 1 million breast cancer cases diagnosed worldwide, 170,000 are of triple negative phenotype (15-20%)[4]. Triple Negative Breast Cancer (TNBC) is a substantially histopathological category based, where there is deficiency of expression of hormone receptors (ER and PR) as well as no transmutation of human epidermal growth factor receptor type 2 (HER2)[3]. They are characterized by poor prognosis and aggressiveness construed by low five-year survival and high recurrence rates after adjuvant therapy. TNBC share arresting correlation with basal-like breast cancers. It is observed with high frequency of BRCA1 mutations and a heightened Ki-67 expression. Taxanes and/or platinum compounds and PARP 1 inhibitors are a good choice of treatment for TNBC[4]. The intent of this review is to highlight the relevance of PARP 1 inhibitors on TNBC and display an in depth discussion regarding these futuristic inhibitors.
KEYWORDS:
Breast Cancer, Triple Negative Breast Cancer, Human Epidermal Growth Factor Receptor, Taxanes, Poly (ADP-ribose) polymerase 1 Inhibitor.
Cite:
Elizabeth Eldhose, B. Gowramma, Manal Mohammed, R. Kalirajan, L. Kaviarasan. Translational Chemotherapy for triple negative Breast Cancer - A Review on significance of poly (ADP-ribose) polymerase 1 (PARP 1) inhibitors. Research J. Pharm. and Tech. 2019; 12(6):3098-3104.
[View HTML]     



Visitor's No. :   594765